Skip to content

Study · In vitro (cells) · rat · 1991

4 results

The effects of insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I, a potent IGF analogue, on growth hormone and IGF-binding protein secretion from cultured rat anterior pituitary cells.

Simes JM, Wallace JC, Walton PE

The Journal of endocrinology1 Jul 1991Cited by 8 (Europe PMC)

PMID1715381 (opens in a new tab)DOI10.1677/joe.0.1300093 (opens in a new tab)PepBankPUB-01715381
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In rat pituitary cells, des(1‑3)IGF-I stimulated GH secretion, with maximal effect at 0.1 micrograms/l.

    In plain wordsIn cells from rat pituitary glands, low concentrations of des(1‑3)IGF-I increased growth hormone release.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseGH secretion at low concentrations
    Study

    ratn: not reported in source

    Cultured anterior pituitary cells
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Maximally effective concentration
    0.1 micrograms/l
    des(1-3)IGF-I

    Source sentences

    Summary
    IGF-I and des(1-3)IGF-I stimulated GH secretion at low concentrations (maximally effective at 1 and 0.1 micrograms/l respectively) and inhibited GH secretion at higher concentrations.
    1 context sentence
    Summary · context
    The effects of insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I, a potent IGF-I analogue, on the secretion of GH and IGF-binding protein (IGFBP) from cultured rat anterior pituitary cells were measured.
  2. 02LabIn vitro (cells)Activity measurement

    In rat pituitary cells, higher des(1‑3)IGF-I concentrations inhibited GH secretion with an approximate IC50 of 1 microgram/l.

    In plain wordsIn cells from rat pituitary glands, higher des(1‑3)IGF-I concentrations reduced growth hormone release.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseGH secretion at higher concentrations
    Study

    ratn: not reported in source

    Cultured anterior pituitary cells
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    IC50
    ≈ 1 microgram/l
    des(1-3)IGF-I

    Source sentences

    Summary
    The half-maximal inhibitory concentrations (IC50) were approximately 20 micrograms/l and 1 microgram/l for IGF-I and des(1-3)IGF-I respectively.
    2 context sentences
    Summary · context
    IGF-I and des(1-3)IGF-I stimulated GH secretion at low concentrations (maximally effective at 1 and 0.1 micrograms/l respectively) and inhibited GH secretion at higher concentrations.
    Summary · context
    The effects of insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I, a potent IGF-I analogue, on the secretion of GH and IGF-binding protein (IGFBP) from cultured rat anterior pituitary cells were measured.
  3. 03LabIn vitro (cell-free)Activity measurement

    In rat pituitary culture medium, IGFBPs bound des(1‑3)IGF-I less than IGF-I and IGF-II.

    In plain wordsIn lab tests, pituitary binding proteins bound des(1‑3)IGF-I less than IGF-I and IGF-II.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreasePituitary IGFBP binding
    Study

    ratn: not reported in source

    Western-ligand blotting and competitive ligand-binding assays of pituitary culture medium
    Comparator
    IGF-I and IGF-II
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    When measured by Western-ligand blotting and competitive ligand-binding techniques, these IGFBPs exhibited decreased binding of des(1-3)IGF-I compared with IGF-I and IGF-II.
    1 context sentence
    Summary · context
    The effects of insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I, a potent IGF-I analogue, on the secretion of GH and IGF-binding protein (IGFBP) from cultured rat anterior pituitary cells were measured.

Studies that did not test the peptide alone1

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 04LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Mechanism

    In rat pituitary cells, added IGFs stimulated IGFBP production, without a separate des(1‑3)IGF-I result.

    In plain wordsIn cells from rat pituitary glands, IGFs increased binding protein production. The abstract did not separate des(1‑3)IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseIGFBP production
    Study

    ratn: not reported in source

    Cultured anterior pituitary cells
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The production of IGFBP by anterior pituitary cells was stimulated by the addition of IGFs to the culture medium.
    1 context sentence
    Summary · context
    The effects of insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I, a potent IGF-I analogue, on the secretion of GH and IGF-binding protein (IGFBP) from cultured rat anterior pituitary cells were measured.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.